Expert Interviews
STOMP Study: Effective Selinexor Regimen in Multitherapy Combo
January 16th 2024Noa Biran, MD, delves into the phase II STOMP study, highlighting selinexor’s efficacy with various backbones like pomalidomide, carfilzomib, daratumumab, and reviews dosing strategies and proactive management of associated toxicities.
Examining Selinexor Role in RRMM Treatment
January 16th 2024Noa Biran, MD, discusses how selinexor targets nuclear export, inducing apoptosis in multiple myeloma cells. Its synergistic potential with approved agents makes it suitable across refractory cases, bridging therapy options and improving patients' quality of life.
.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "Treatment Approaches for Resectable Stage-III NSCLC in the Adjuvant Setting")
Treatment Approaches for Resectable Stage-III NSCLC in the Adjuvant Setting
January 16th 2024Vinay Raja, MD, explores the crucial role of adjuvant immunotherapy in resectable stage III NSCLC, providing insights into patient selection criteria, considerations for choosing among available treatment options, and the impact of recent trial data updates on informing treatment decisions in this evolving therapeutic landscape.
Expert Perspectives on Perioperative Immunotherapy in Resectable Stage-III NSCLC
January 16th 2024Oncology experts from the University of Kansas discuss the evolving role of neoadjuvant/perioperative immunotherapy in resectable stage-III NSCLC, analyzing recent trial data and addressing the nuanced factors that inform their decisions between neoadjuvant and perioperative treatments in clinical practice.
Determining Eligibility for Surgical Resection in NSCLC
January 16th 2024Alykhan Nagji, MD, provides an overview of the institutional approach to determining eligibility for surgical resection, delving into the pivotal role of the multidisciplinary tumor board in the decision-making process and exploring the crucial factors that must be considered when evaluating resectability.
Real-World Data Highlight Male Breast Cancer Population Outcome Disparities
January 15th 2024Black male patients with breast cancer appear to experience worse survival outcomes compared with White patients when controlling for clinicopathological variables, according to Jason (Jincong) Q. Freeman, MPH, MS.
Pembrolizumab/Chemoradiotherapy Approval is ‘Huge Win’ in Cervical Cancer
January 12th 2024Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
2-Minute Drill: Closing Thoughts on the 2023 ASH Annual Meeting
January 12th 2024Joshua Richter, MD, of Mount Sinai, and other hematologic cancer experts join CancerNetwork following the 2023 ASH Annual Meeting & Exposition to share their closing thoughts before the 2-Minute Drill winner is announced.
Defining Success in Multiple Myeloma Induction and Maintenance
January 12th 2024Three physicians explore the criteria for determining an adequate or successful response during the induction phase in patients with TE NDMM and uncover the intricate considerations shaping the choice of maintenance regimens.
